You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer

Janjigian, Yelena Y. MD*; Ku, Geoffrey Y. MD, PhD*; Campbell, Jenny C.*; Shah, Manish A. MD*; Capanu, Marinela PhD; Kelsen, David P. MD*; Ilson, David H. MD, PhD*

American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e318271b14f
Original Articles: Gastrointestinal
Abstract

Introduction: Cetuximab in combination with irinotecan has shown clinically significant activity in patients with irinotecan-refractory colon cancer. We evaluated the efficacy of cetuximab in combination with cisplatin and irinotecan in patients with metastatic esophagogastric cancer refractory to cisplatin and irinotecan.

Patients and Methods: Patients with disease progression within 3 months of treatment with prior cisplatin and irinotecan received weekly cetuximab and cisplatin/irinotecan for 2 weeks, followed by a 1-week rest period. The primary endpoint was objective response rate. Secondary endpoints included progression-free and overall survival.

Results: Sixteen patients were enrolled (87% with adenocarcinoma). The median prior exposure to cisplatin/irinotecan was 3.6 months. The addition of cetuximab to cisplatin and irinotecan was well tolerated and there were no unexpected toxicities. One of 16 patients treated on study experienced durable RECIST partial response lasting 10 months. The median progression-free survival was 1.4 months (range, 0.5 to10 mo).

Conclusions: The addition of cetuximab did not overcome irinotecan resistance in patients with metastatic esophagogastric cancer. Further investigation of this strategy in esophagogastric cancer is not justified. The limited activity observed for cetuximab is consistent with other studies evaluating single-agent cetuximab.

Author Information

*Department of Medicine, Gastrointestinal Oncology Service

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY

Supported in part by Bristol-Myers Squibb.

The authors declare no conflicts of interest.

Reprints: Yelena Y. Janjigian, MD, Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 300 E66th Street, New York, NY 10065. E-mail: janjigiy@mskcc.org.

© 2014 by Lippincott Williams & Wilkins, Inc